Steven Potts, PhD, MBA
COFOUNDER, CEO AND DIRECTOR, ONCOMYX THERAPEUTICS
Phoenix, Arizona, United States
Steven has worked in biopharma since 1999 with experience in product development, sales, marketing, and management. He has a proven track record of success, with his last three companies all with significant shareholder returns. He was VP of Medical Affairs at Ignyta, which was acquired by Roche for $1.7B, and he led the global operation of testing of 30,000 patients in an oncology basket trial for entrectinib in 15 countries. The molecule was the first in industry to receive breakthrough designation equivalents in USA, Europe, and Japan. Prior to Ignyta, he was founding CEO of Flagship Biosciences, to 75 employees and an exit for his investors. He was General Manager Life Sciences at Aperio, which exited to Danaher for $180M. He built the Bioinformatics Department for Fortune 500 Company Quest Diagnostics, which delivered $1B of annual revenue. He earned a BS in Physics from Wheaton College, Illinois and PhD in Biological Engineering and MBA from the University of California Davis.